Turtle study: A phase II study of durvalumab plus carboplatin and etoposide in elderly patients with extensive-stage small-cell lung cancer (LOGiK 2003)
Hidenobu Ishii; Koichi Azuma; Yuta Yamanaka; Hiroshige Yoshioka; Yukihiro Toi; Naoki Shingu; Katsuhiko Naoki; Masaki Okamoto; Yuko Tsuchiya-Kawano; Taishi Harada; Hiroyuki Inoue; Hiroshi Ishii; Kazuori Tobino; Chiho Nakashima; Yoshifusa Koreeda; Yasushi Hisamatsu; Shinsuke Tsumura; Takashi Inagaki; Keiko Mizuno; Takayuki Shimose; Isamu Okamoto
JTO Clinical and Research Reports, Apr. 2025

Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation.
Shintaro Kanda; Seiji Niho; Takayasu Kurata; Shogo Nomura; Yosuke Kawashima; Eiji Iwama; Toshihide Yokoyama; Yasutaka Watanabe; Hiroshi Tanaka; Yutaka Fujiwara; Yoshitaka Zenke; Koichi Azuma; Hirokazu Taniguchi; Ryo Toyozawa; Yukio Hosomi; Haruyasu Murakami; Satoshi Hara; Akihiro Bessho; Nobuyuki Yamamoto; Yuichiro Ohe
Clinical cancer research : an official journal of the American Association for Cancer Research, 31 Mar. 2025

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50.
Yoshihito Kogure; Hiroya Hashimoto; Haruko Daga; Yasushi Fukuda; Akihiro Bessho; Tadaaki Yamada; Yukihiro Toi; Tomoki Kimura; Hiroshige Yoshioka; Koichi Azuma; Naoki Furuya; Yasutaka Fukui; Akiko M Saito; Nobuyuki Yamamoto; Hideo Saka; Masashi Kondo
JTO clinical and research reports, Mar. 2025

The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer.
Daiki Murata; Koichi Azuma; Yuuya Nishii; Kenta Murotani; Goushi Matama; Akihiko Kawahara; Takaaki Tokito; Tetsuro Sasada; Tomoaki Hoshino
Chemotherapy, 22 Jan. 2025

A single-arm, phase II study of sotorasib plus carboplatin/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET).
Hiroaki Akamatsu; Shinya Sakata; Koichi Azuma; Hiroshige Yoshioka; Takehiro Uemura; Yuko Tsuchiya-Kawano; Seiya Esumi; Takashi Kurosaki; Yuki Sato; Tomohiro Sakamoto; Kiichiro Ninomiya; Ryo Toyozawa; Yasuto Yoneshima; Takehito Shukuya; Toshiyuki Kozuki; Kana Watanabe; Haruko Daga; Terufumi Kato; Toshiaki Takahashi; Mitsuo Osuga; Yasuhiro Koh; Satoshi Morita; Nobuyuki Yamamoto
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 17 Jan. 2025

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).
Tomoya Fukui; Nobuaki Mamesaya; Toshiaki Takahashi; Kazuma Kishi; Takahiro Yoshizawa; Takaaki Tokito; Koichi Azuma; Kei Morikawa; Satoshi Igawa; Yusuke Okuma; Yuta Yamanaka; Shinobu Hosokawa; Takashi Kasai; Ken Masubuchi; Shinji Nakamichi; Masaharu Aga; Jiichiro Sasaki; Akiko Kada; Akiko M Saito; Katsuhiko Naoki; Hiroaki Okamoto
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 02 Jan. 2025

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.
Yosuke Kakiuchi; Koichi Saruwatari; Kenta Murotani; Takaaki Tokito; Toyohisa Iriki; Jun Iwakawa; Yoshihiko Sakata; Naoki Shingu; Sho Saeki; Megumi Inaba; Akira Takaki; Shunsuke Misono; Takayuki Suetsugu; Koichi Azuma; Keiko Mizuno; Takuro Sakagami
Clinical lung cancer, Dec. 2024

Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Yoshimasa Shiraishi; Shogo Nomura; Shunichi Sugawara; Hidehito Horinouchi; Yasuto Yoneshima; Hidetoshi Hayashi; Koichi Azuma; Satoshi Hara; Seiji Niho; Ryo Morita; Masafumi Yamaguchi; Toshihide Yokoyama; Kiyotaka Yoh; Takayasu Kurata; Hiroaki Okamoto; Masaki Okamoto; Takashi Kijima; Kazuo Kasahara; Yutaka Fujiwara; Shuji Murakami; Shintaro Kanda; Hiroaki Akamatsu; Shinnosuke Takemoto; Hiroyasu Kaneda; Toshiyuki Kozuki; Masahiko Ando; Yuta Sekino; Haruhiko Fukuda; Yuichiro Ohe; Isamu Okamoto
The Lancet. Respiratory medicine, Nov. 2024

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study.
Hirotsugu Kenmotsu; Kazuko Sakai; Keita Mori; Terufumi Kato; Shunichi Sugawara; Keisuke Kirita; Yasuto Yoneshima; Koichi Azuma; Kazumi Nishino; Shunsuke Teraoka; Ryo Koyama; Ken Masuda; Hidetoshi Hayashi; Ryo Toyozawa; Satoru Miura; Yuki Sato; Kazuhiko Nakagawa; Nobuyuki Yamamoto; Kazuto Nishio; Toshiaki Takahashi
JTO clinical and research reports, Nov. 2024

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
Yuki Kato; Hibiki Udagawa; Shingo Matsumoto; Hiroki Izumi; Yuichiro Ohe; Terufumi Kato; Kazumi Nishino; Shingo Miyamoto; Sachiko Kawana; Kenichi Chikamori; Masato Shingyoji; Yuki Sato; Yuji Takada; Ryo Toyozawa; Koichi Azuma; Yu Tanaka; Tetsuya Sakai; Yuji Shibata; Eri Sugiyama; Kaname Nosaki; Yoshitaka Zenke; Shigeki Umemura; Kiyotaka Yoh; Masahiro Seike; Koichi Goto
Lung cancer (Amsterdam, Netherlands), Nov. 2024

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Kiyotaka Yoh; Koichi Azuma; Hidetoshi Hayashi; Makoto Nishio; Kenichi Chikamori; Eiki Ichihara; Yasutaka Watanabe; Takayuki Asato; Tadayuki Kitagawa; Robert J Fram; Yuichiro Ohe
International journal of clinical oncology, Oct. 2024

A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvement.
Takehiko Manabe; Masatoshi Kanayama; Hiroki Matsumiya; Katsuma Yoshimatsu; Masataka Mori; Natsumasa Nishizawa; Akihiro Taira; Masaru Takenaka; Koji Kuroda; Koichi Azuma; Fumihiro Tanaka
General Thoracic and Cardiovascular Surgery Cases, 01 Oct. 2024

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.
Daiki Murata; Koichi Azuma; Kenta Murotani; Akihiko Kawahara; Yuuya Nishii; Takaaki Tokito; Tetsuro Sasada; Tomoaki Hoshino
Cancer immunology, immunotherapy : CII, 05 Sep. 2024

Thoracic Angiosarcoma Arising from Chronic Tuberculous Pyothorax: A Case Report.
Takayuki Horii; Jun Sasaki; Hidenobu Ishii; Misa Sudou; Reiko Takaki; Takaaki Tokito; Koichi Azuma; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 04 Sep. 2024

Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Shun Horaguchi; Yoshiro Nakahara; Yuka Igarashi; Taku Kouro; Feifei Wei; Kenta Murotani; Seiichi Udagawa; Naoko Higashijima; Norikazu Matsuo; Shuji Murakami; Terufumi Kato; Tetsuro Kondo; Huihui Xiang; Rika Kasajima; Hidetomo Himuro; Kayoko Tsuji; Yasunobu Mano; Mitsuru Komahashi; Yohei Miyagi; Haruhiro Saito; Koichi Azuma; Shuichiro Uehara; Tetsuro Sasada
Biomedicines, 12 Aug. 2024

First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.
Hisao Imai; Takashi Kijima; Koichi Azuma; Kazuma Kishi; Haruhiro Saito; Teppei Yamaguchi; Junko Tanizaki; Yasuto Yoneshima; Kohei Fujita; Satoshi Watanabe; Satoru Kitazono; Tatsuro Fukuhara; Osamu Hataji; Yukihiro Toi; Hideaki Mizutani; Yusuke Hamakawa; Makoto Maemondo; Tomoyuki Ohsugi; Keisuke Suzuki; Hidehito Horinouchi; Yuichiro Ohe
Japanese journal of clinical oncology, 06 Apr. 2024

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Yoshimasa Shiraishi; Junji Kishimoto; Shunichi Sugawara; Hideaki Mizutani; Haruko Daga; Koichi Azuma; Hirotaka Matsumoto; Osamu Hataji; Kazumi Nishino; Masahide Mori; Takehito Shukuya; Haruhiro Saito; Motoko Tachihara; Hidetoshi Hayashi; Asuka Tsuya; Kazushige Wakuda; Noriko Yanagitani; Tomohiro Sakamoto; Satoru Miura; Akito Hata; Morihito Okada; Toshiyuki Kozuki; Yuki Sato; Taishi Harada; Koichi Takayama; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Isamu Okamoto
JAMA oncology, 01 Mar. 2024

Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort.
Makoto Nishio; Shuji Murakami; Hisato Kawakami; Kyoichi Okishio; Motohiro Tamiya; Haruki Kobayashi; Daichi Fujimoto; Shunichi Sugawara; Toshiyuki Kozuki; Yuko Oya; Hiroki Izumi; Takayuki Shiroyama; Miyako Satouchi; Noboru Yamamoto; Shota Kaname; Daiko Matsuoka; Yohei Otake; Takao Takase; Taro Semba; Koichi Azuma
Cancer research communications, 29 Jan. 2024

Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.
Daisuke Hazama; Kenji Nakahama; Hiroaki Kodama; Akito Miyazaki; Koichi Azuma; Yosuke Kawashima; Yuki Sato; Kentaro Ito; Yoshimasa Shiraishi; Keita Miura; Takayuki Takahama; Satoshi Oizumi; Yoshinobu Namba; Satoshi Ikeda; Hiroshige Yoshioka; Asuka Tsuya; Yuichiro Yasuda; Yoshiki Negi; Ayako Hara; Michihito Toda; Motoko Tachihara
JTO clinical and research reports, Jan. 2024

Multi-omics analysis-based clinical and functional significance of a novel prognostic and immunotherapeutic gene signature derived from amino acid metabolism pathways in lung adenocarcinoma.
Huihui Xiang; Rika Kasajima; Koichi Azuma; Tomoyuki Tagami; Asami Hagiwara; Yoshiro Nakahara; Haruhiro Saito; Yuka Igarashi; Feifei Wei; Tatsuma Ban; Mitsuyo Yoshihara; Yoshiyasu Nakamura; Shinya Sato; Shiro Koizume; Tomohiko Tamura; Tetsuro Sasada; Yohei Miyagi
Frontiers in immunology, 2024

Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Takehiro Uemura; Hirotsugu Kenmotsu; Daisuke Hazama; Shunsuke Teraoka; Hiroshi Kobe; Koichi Azuma; Teppei Yamaguchi; Takeshi Masuda; Toshihide Yokoyama; Kohei Otsubo; Koji Haratani; Daisuke Hayakawa; Masahide Oki; Shinnosuke Takemoto; Tomohiro Ozaki; Yusaku Akashi; Akito Hata; Hiroya Hashimoto; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Cancer medicine, Dec. 2023

Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
Motoko Tachihara; Kayoko Tsujino; Takeaki Ishihara; Hidetoshi Hayashi; Yuki Sato; Takayasu Kurata; Shunichi Sugawara; Yoshimasa Shiraishi; Shunsuke Teraoka; Koichi Azuma; Haruko Daga; Masafumi Yamaguchi; Takeshi Kodaira; Miyako Satouchi; Mototsugu Shimokawa; Nobuyuki Yamamoto; Kazuhiko Nakagawa
JAMA oncology, 01 Nov. 2023

Proton Beam Therapy as a Curative Treatment for a Young Case of Unresectable Tracheal Adenoid Cystic Carcinoma.
Takashi Kinoshita; Hidenobu Ishii; Yuki Sakazaki; Koichi Azuma; Jun Sasaki; Takaaki Tokito; Masaki Tominaga; Etsuyo Ogou; Tomotaka Kawayama; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 01 Oct. 2023

Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Daiki Murata; Koichi Azuma; Kenta Murotani; Norikazu Matsuo; Goushi Matama; Takaaki Tokito; Tetsuro Sasada; Tomoaki Hoshino
Lung cancer (Amsterdam, Netherlands), Oct. 2023

Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.
Daiki Murata; Koichi Azuma; Norikazu Matsuo; Kenta Murotani; Goushi Matama; Akihiko Kawahara; Tetsuro Sasada; Takaaki Tokito; Tomoaki Hoshino
Cancer medicine, Oct. 2023

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Kimio Yonesaka; Hidetoshi Hayashi; Atsushi Nakamura; Yuki Sato; Koichi Azuma; Shinya Sakata; Motoko Tachihara; Satoshi Ikeda; Toshihide Yokoyama; Kentaro Ito; Yukihiro Yano; Hirotaka Matsumoto; Haruko Daga; Akito Hata; Kazuko Sakai; Yasutaka Chiba; Kazuto Nishio; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Clinical lung cancer, Sep. 2023

Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Martin Reck; Tudor-Eliade Ciuleanu; Jong-Seok Lee; Michael Schenker; Bogdan Zurawski; Sang-We Kim; Mauricio Mahave; Aurelia Alexandru; Solange Peters; Adam Pluzanski; Reyes Bernabe Caro; Helena Linardou; Jacobus A Burgers; Makoto Nishio; Alex Martinez-Marti; Koichi Azuma; Rita Axelrod; Luis G Paz-Ares; Suresh S Ramalingam; Hossein Borghaei; Kenneth J O'Byrne; Li Li; Judith Bushong; Ravi G Gupta; Diederik J Grootendorst; Laura J Eccles; Julie R Brahmer
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Aug. 2023

Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Hidetomo Himuro; Yoshiro Nakahara; Yuka Igarashi; Taku Kouro; Naoko Higashijima; Norikazu Matsuo; Shuji Murakami; Feifei Wei; Shun Horaguchi; Kayoko Tsuji; Yasunobu Mano; Haruhiro Saito; Koichi Azuma; Tetsuro Sasada
Cancer immunology, immunotherapy : CII, Aug. 2023

Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Feifei Wei; Koichi Azuma; Yoshiro Nakahara; Haruhiro Saito; Norikazu Matsuo; Tomoyuki Tagami; Taku Kouro; Yuka Igarashi; Takaaki Tokito; Terufumi Kato; Tetsuro Kondo; Shuji Murakami; Ryo Usui; Hidetomo Himuro; Shun Horaguchi; Kayoko Tsuji; Kenta Murotani; Tatsuma Ban; Tomohiko Tamura; Yohei Miyagi; Tetsuro Sasada
Journal for immunotherapy of cancer, Jul. 2023

Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Kenji Morimoto; Tadaaki Yamada; Ryo Sawada; Koichi Azuma; Yasuhiro Goto; Taishi Harada; Shinsuke Shiotsu; Nobuyo Tamiya; Yusuke Chihara; Takayuki Takeda; Osamu Hiranuma; Isao Hasegawa; Satomi Tanaka; Akihiro Yoshimura; Masahiro Iwasaku; Shinsaku Tokuda; Young Hak Kim; Koichi Takayama
Cancer immunology, immunotherapy : CII, Jun. 2023

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Ryota Saito; Shunichi Sugawara; Ryo Ko; Koichi Azuma; Ryo Morita; Makoto Maemondo; Satoshi Oizumi; Kazuhisa Takahashi; Hiroshi Kagamu; Yukari Tsubata; Masahiro Seike; Toshiaki Kikuchi; Isamu Okamoto; Morita Satoshi; Hajime Asahina; Kentaro Tanaka; Kenji Sugio; Kunihiko Kobayashi
European journal of cancer (Oxford, England : 1990), May 2023

Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Norikazu Matsuo; Koichi Azuma; Kenta Murotani; Daiki Murata; Goushi Matama; Akihiko Kawahara; Takashi Kojima; Takaaki Tokito; Tomoaki Hoshino
Thoracic cancer, May 2023

Enhanced immune complex formation in the lungs of patients with dermatomyositis.
Yoshiaki Zaizen; Masaki Okamoto; Koichi Azuma; Junya Fukuoka; Hironao Hozumi; Noriho Sakamoto; Takafumi Suda; Hiroshi Mukae; Tomoaki Hoshino
Respiratory research, 19 Mar. 2023

A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
Masayuki Takeda; Mototsugu Shimokawa; Atsushi Nakamura; Kaname Nosaki; Yasutaka Watanabe; Terufumi Kato; Daisuke Hayakawa; Hiroshi Tanaka; Toshiaki Takahashi; Masahide Oki; Motoko Tachihara; Daichi Fujimoto; Hidetoshi Hayashi; Kakuhiro Yamaguchi; Shoichiro Yamamoto; Eiji Iwama; Koichi Azuma; Kazuo Hasegawa; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Lung cancer (Amsterdam, Netherlands), Mar. 2023

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
Satoru Miura; Yasuhiro Koh; Koichi Azuma; Hiroshige Yoshioka; Kenichi Koyama; Shunsuke Teraoka; Hidenobu Ishii; Kayoko Kibata; Yuichi Ozawa; Takaaki Tokito; Jun Oyanagi; Toshio Shimokawa; Takayasu Kurata; Nobuyuki Yamamoto; Hiroshi Tanaka
BMC cancer, 03 Jan. 2023

Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Daiki Murata; Koichi Azuma; Goushi Matama; Yoshiaki Zaizen; Norikazu Matsuo; Kenta Murotani; Takaaki Tokito; Tomoaki Hoshino
Thoracic cancer, Jan. 2023

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003).
Hidenobu Ishii; Koichi Azuma; Takayuki Shimose; Hiroshige Yoshioka; Takayasu Kurata; Naoki Shingu; Masaki Okamoto; Yosuke Kawashima; Isamu Okamoto
Thoracic cancer, Jan. 2023

Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors.
Yoshiro Nakahara; Taku Kouro; Satoru Motoyama; Masatomo Miura; Kazuma Fujita; Yuka Igarashi; Naoko Higashijima; Norikazu Matsuo; Hidetomo Himuro; Feifei Wei; Shun Horaguchi; Kayoko Tsuji; Yasunobu Mano; Mitsuru Komahashi; Haruhiro Saito; Koichi Azuma; Tetsuro Sasada
Frontiers in cell and developmental biology, 2023

A case of cytokine release syndrome accompanied with COVID-19 infection during treatment with immune checkpoint inhibitors for non-small cell lung cancer.
Daiki Murata; Koichi Azuma; Saeko Tokisawa; Takaaki Tokito; Tomoaki Hoshino
Thoracic cancer, Oct. 2022

Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Hirotsugu Kenmotsu; Kazushige Wakuda; Keita Mori; Terufumi Kato; Shunichi Sugawara; Keisuke Kirita; Yasuto Yoneshima; Koichi Azuma; Kazumi Nishino; Shunsuke Teraoka; Takehito Shukuya; Ken Masuda; Hidetoshi Hayashi; Ryo Toyozawa; Satoru Miura; Daichi Fujimoto; Kazuhiko Nakagawa; Nobuyuki Yamamoto; Toshiaki Takahashi
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Sep. 2022

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC.
Kenji Morimoto; Ryo Sawada; Tadaaki Yamada; Koichi Azuma; Kentaro Ito; Yasuhiro Goto; Hideharu Kimura; Taishi Harada; Shinsuke Shiotsu; Nobuyo Tamiya; Yusuke Chihara; Takayuki Takeda; Osamu Hiranuma; Isao Hasegawa; Yoshie Morimoto; Masahiro Iwasaku; Shinsaku Tokuda; Koichi Takayama
JTO clinical and research reports, Sep. 2022

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Hidetoshi Hayashi; Kimio Yonesaka; Atsushi Nakamura; Daichi Fujimoto; Koichi Azuma; Shinya Sakata; Motoko Tachihara; Satoshi Ikeda; Toshihide Yokoyama; Osamu Hataji; Yukihiro Yano; Katsuya Hirano; Haruko Daga; Hideaki Okada; Yasutaka Chiba; Kazuko Sakai; Kazuto Nishio; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Lung cancer (Amsterdam, Netherlands), Jun. 2022

AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.
Yuichi Murakami; Daiki Kusakabe; Kosuke Watari; Akihiko Kawahara; Koichi Azuma; Jun Akiba; Masahiko Taniguchi; Michihiko Kuwano; Mayumi Ono
Scientific reports, 28 May 2022

Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
Naoki Haratake; Hidetoshi Hayashi; Mototsugu Shimokawa; Yusuke Nakano; Koichi Azuma; Masahide Oki; Keiichi Ota; Hiroshige Yoshioka; Tomohiro Sakamoto; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Takashi Seto
Clinical lung cancer, May 2022

Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model.
Koichi Azuma; Huihui Xiang; Tomoyuki Tagami; Rika Kasajima; Yumiko Kato; Sachise Karakawa; Shinya Kikuchi; Akira Imaizumi; Norikazu Matsuo; Hidenobu Ishii; Takaaki Tokito; Akihiko Kawahara; Kenta Murotani; Tetsuro Sasada; Yohei Miyagi; Tomoaki Hoshino
Journal for immunotherapy of cancer, May 2022

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hidetoshi Hayashi; Shunichi Sugawara; Yasushi Fukuda; Daichi Fujimoto; Satoru Miura; Keiichi Ota; Yuichi Ozawa; Satoshi Hara; Junko Tanizaki; Koichi Azuma; Shota Omori; Motoko Tachihara; Kazumi Nishino; Akihiro Bessho; Yasutaka Chiba; Koji Haratani; Kazuko Sakai; Kazuto Nishio; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Clinical cancer research : an official journal of the American Association for Cancer Research, 01 Mar. 2022

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Takashi Seto; Kaname Nosaki; Mototsugu Shimokawa; Ryo Toyozawa; Shunichi Sugawara; Hidetoshi Hayashi; Haruyasu Murakami; Terufumi Kato; Seiji Niho; Hideo Saka; Masahide Oki; Hiroshige Yoshioka; Isamu Okamoto; Haruko Daga; Koichi Azuma; Hiroshi Tanaka; Kazumi Nishino; Rie Tohnai; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Journal for immunotherapy of cancer, Feb. 2022

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Yosuke Kawashima; Tatsuro Fukuhara; Haruhiro Saito; Naoki Furuya; Kana Watanabe; Shunichi Sugawara; Shunichiro Iwasawa; Yoshio Tsunezuka; Ou Yamaguchi; Morihito Okada; Kozo Yoshimori; Ichiro Nakachi; Masahiro Seike; Koichi Azuma; Futoshi Kurimoto; Yukari Tsubata; Yuka Fujita; Hiromi Nagashima; Gyo Asai; Satoshi Watanabe; Masaki Miyazaki; Koichi Hagiwara; Toshihiro Nukiwa; Satoshi Morita; Kunihiko Kobayashi; Makoto Maemondo
The Lancet. Respiratory medicine, Jan. 2022

Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
Yoshiro Nakahara; Takaji Matsutani; Yuka Igarashi; Norikazu Matsuo; Hidetomo Himuro; Haruhiro Saito; Kouzo Yamada; Kenta Murotani; Tomoaki Hoshino; Koichi Azuma; Tetsuro Sasada
Cancer immunology, immunotherapy : CII, Oct. 2021

Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
Norikazu Matsuo; Koichi Azuma; Takashi Kojima; Hidenobu Ishii; Takaaki Tokito; Kazuhiko Yamada; Tomoaki Hoshino
Investigational new drugs, Aug. 2021

A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L).
Masayuki Takeda; Mototsugu Shimokawa; Atsushi Nakamura; Kaname Nosaki; Yasutaka Watanabe; Terufumi Kato; Daisuke Hayakawa; Hiroshi Tanaka; Toshiaki Takahashi; Yoshihito Kogure; Motoko Tachihara; Daichi Fujimoto; Kakuhiro Yamaguchi; Naohiko Hamaguchi; Isamu Okamoto; Koichi Azuma; Kazuo Hasegawa; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Clinical lung cancer, Jul. 2021

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis.
Katsuyuki Hotta; Makoto Nishio; Haruhiro Saito; Isamu Okamoto; Yasuharu Nakahara; Hidetoshi Hayashi; Manabu Hayama; Peter Laud; Haiyi Jiang; Luis Paz-Ares; Koichi Azuma
International journal of clinical oncology, Jun. 2021

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Hiroaki Akamatsu; Yukihiro Toi; Hidetoshi Hayashi; Daichi Fujimoto; Motoko Tachihara; Naoki Furuya; Sakiko Otani; Junichi Shimizu; Nobuyuki Katakami; Koichi Azuma; Naoko Miura; Kazumi Nishino; Satoshi Hara; Shunsuke Teraoka; Satoshi Morita; Kazuhiko Nakagawa; Nobuyuki Yamamoto
JAMA oncology, 01 Mar. 2021

Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
Kentaro Ito; Takeharu Yamanaka; Hidetoshi Hayashi; Yoshihiro Hattori; Kazumi Nishino; Haruki Kobayashi; Yuko Oya; Toshihide Yokoyama; Takashi Seto; Koichi Azuma; Tomoya Fukui; Toshiyuki Kozuki; Atsushi Nakamura; Kentaro Tanaka; Katsuya Hirano; Takashi Yokoi; Haruko Daga; Shinya Sakata; Daichi Fujimoto; Masahide Mori; Ken Maeno; Takuya Aoki; Atsuhisa Tamura; Satoru Miura; Satoshi Watanabe; Hiroaki Akamatsu; Osamu Hataji; Kensuke Suzuki; Shigeto Hontsu; Koji Azuma; Akihiro Bessho; Akihito Kubo; Motoyasu Okuno; Kazuhiko Nakagawa; Nobuyuki Yamamoto
European journal of cancer (Oxford, England : 1990), Mar. 2021

Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Hidenobu Ishii; Koichi Azuma; Akihiko Kawahara; Norikazu Matsuo; Takaaki Tokito; Tomoaki Hoshino
Investigational new drugs, Feb. 2021

Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Kazuko Sakai; Takayuki Takahama; Mototsugu Shimokawa; Koichi Azuma; Masayuki Takeda; Terufumi Kato; Haruko Daga; Isamu Okamoto; Hiroaki Akamatsu; Shunsuke Teraoka; Akira Ono; Tatsuo Ohira; Toshihide Yokoyama; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Kazuto Nishio
Molecular oncology, Jan. 2021

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations.
Ryo Ko; Takehito Shukuya; Chiyo K Imamura; Takaaki Tokito; Naoko Shimada; Ryo Koyama; Kazuhiko Yamada; Hidenobu Ishii; Koichi Azuma; Kazuhisa Takahashi
Translational lung cancer research, Jan. 2021

Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L).
Motoko Tachihara; Kayoko Tsujino; Takeaki Ishihara; Hidetoshi Hayashi; Yuki Sato; Takayasu Kurata; Shunichi Sugawara; Isamu Okamoto; Shunsuke Teraoka; Koichi Azuma; Haruko Daga; Masafumi Yamaguchi; Takeshi Kodaira; Miyako Satouchi; Mototsugu Shimokawa; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Cancer management and research, 2021

Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy.
Takeharu Ono; Koichi Azuma; Akihiko Kawahara; Tatsuyuki Kakuma; Fumihiko Sato; Jun Akiba; Norimitsu Tanaka; Toshi Abe; Shun-Ichi Chitose; Hirohito Umeno
Head & neck, Dec. 2020

Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Kazuki Takada; Gouji Toyokawa; Fumihiko Kinoshita; Tomoko Jogo; Kenichi Kohashi; Sho Wakasu; Yuki Ono; Kensuke Tanaka; Taro Oba; Atsushi Osoegawa; Tetsuzo Tagawa; Koichi Azuma; Isamu Okamoto; Mototsugu Shimokawa; Yoshinao Oda; Masaki Mori
Journal of cancer research and clinical oncology, Oct. 2020

Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Yoshimasa Shiraishi; Junji Kishimoto; Kentaro Tanaka; Shunichi Sugawara; Haruko Daga; Katsuya Hirano; Koichi Azuma; Osamu Hataji; Hidetoshi Hayashi; Motoko Tachihara; Tetsuya Mitsudomi; Takashi Seto; Kazuhiko Nakagawa; Nobuyuki Yamamoto; Isamu Okamoto
Clinical lung cancer, Sep. 2020

Changes in immune parameters between pre-treatment and recurrence after (chemo) radiation therapy in patients with head and neck cancer.
Takeharu Ono; Koichi Azuma; Akihiko Kawahara; Tatsuyuki Kakuma; Fumihiko Sato; Toshihiko Kawaguchi; Jun Akiba; Hirohito Umeno
Scientific reports, 20 Jul. 2020

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
Shingo Miyamoto; Koichi Azuma; Hidenobu Ishii; Akihiro Bessho; Shinobu Hosokawa; Nobuaki Fukamatsu; Hideo Kunitoh; Mari Ishii; Hiroshi Tanaka; Hiromi Aono; Yoshiro Nakahara; Kei Kusaka; Yukio Hosomi; Norihiro Kikuchi; Yoshiaki Mori; Hidetoshi Itani; Akinobu Hamada; Kazuhiko Yamada; Hiroaki Okamoto
JAMA oncology, 01 Jul. 2020

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study.
Tatsuro Fukuhara; Haruhiro Saito; Naoki Furuya; Kana Watanabe; Shunichi Sugawara; Shunichiro Iwasawa; Yoshio Tsunezuka; Ou Yamaguchi; Prof Morihito Okada; Kozo Yoshimori; Ichiro Nakachi; Prof Akihiko Gemma; Koichi Azuma; Futoshi Kurimoto; Yukari Tsubata; Yuka Fujita; Hiromi Nagashima; Gyo Asai; Satoshi Watanabe; Masaki Miyazaki; Prof Koichi Hagiwara; Prof Toshihiro Nukiwa; Prof Satoshi Morita; Prof Kunihiko Kobayashi; Prof Makoto Maemondo
EBioMedicine, Jul. 2020

Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Isamu Okamoto; Hiroshi Nokihara; Shogo Nomura; Seiji Niho; Shunichi Sugawara; Hidehito Horinouchi; Koichi Azuma; Yasuto Yoneshima; Haruyasu Murakami; Yukio Hosomi; Shinji Atagi; Tomohiro Ozaki; Atsushi Horiike; Yuka Fujita; Hiroaki Okamoto; Masahiko Ando; Nobuyuki Yamamoto; Yuichiro Ohe; Kazuhiko Nakagawa
JAMA oncology, 01 May 2020

Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Hidenobu Ishii; Koichi Azuma; Akihiko Kawahara; Takashi Kinoshita; Norikazu Matsuo; Yoshiko Naito; Takaaki Tokito; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Thoracic cancer, Apr. 2020

Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L).
Takashi Seto; Koichi Azuma; Takeharu Yamanaka; Shunichi Sugawara; Hiroshige Yoshioka; Kazushige Wakuda; Shinji Atagi; Yasuo Iwamoto; Hidetoshi Hayashi; Isamu Okamoto; Hideo Saka; Shigeki Mitsuoka; Daichi Fujimoto; Kazumi Nishino; Atsushi Horiike; Haruko Daga; Takashi Sone; Nobuyuki Yamamoto; Kazuhiko Nakagawa; Yoichi Nakanishi
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 10 Mar. 2020

Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
Kiminobu Sato; Takeharu Ono; Fumihiko Sato; Akihiko Kawahara; Koichi Azuma; Toshihiko Kawaguchi; Jun Akiba; Hirohito Umeno
Oral oncology, Feb. 2020

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib.
Hidenobu Ishii; Koichi Azuma; Kazuko Sakai; Yoshiko Naito; Norikazu Matsuo; Takaaki Tokito; Kazuhiko Yamada; Tomoaki Hoshino; Kazuto Nishio
Scientific reports, 20 Jan. 2020

Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Eiji Iwama; Kazuko Sakai; Noriko Hidaka; Koji Inoue; Akiko Fujii; Noriaki Nakagaki; Keiichi Ota; Ryo Toyozawa; Koichi Azuma; Keita Nakatomi; Taishi Harada; Junko Hisasue; Shinya Sakata; Takayuki Shimose; Junji Kishimoto; Yoichi Nakanishi; Kazuto Nishio; Isamu Okamoto
Cancer, 01 Jan. 2020

Prognostic value of dual-point fluorine-18 fluorodeoxyglucose PET imaging, partial volume correction and glucose transporter-1 expression in resected nonsmall cell lung cancer patients.
Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Shinzo Takamori; Jun Akiba; Kiminori Fujimoto; Kazunari Ishii; Masatoshi Ishibashi
Nuclear medicine communications, Jan. 2020

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Kazuhiko Nakagawa; Toyoaki Hida; Hiroshi Nokihara; Masahiro Morise; Koichi Azuma; Young Hak Kim; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Toru Kumagai; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Ryo Koyama; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Morihiko Hayashi; Wakako Hasegawa; Tomohide Tamura
Lung cancer (Amsterdam, Netherlands), Jan. 2020

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takayuki Takahama; Koichi Azuma; Mototsugu Shimokawa; Masayuki Takeda; Hidenobu Ishii; Terufumi Kato; Haruhiro Saito; Haruko Daga; Yuko Tsuboguchi; Isamu Okamoto; Kohei Otsubo; Hiroaki Akamatsu; Shunsuke Teraoka; Toshiaki Takahashi; Akira Ono; Tatsuo Ohira; Toshihide Yokoyama; Kazuko Sakai; Nobuyuki Yamamoto; Kazuto Nishio; Kazuhiko Nakagawa
Cancer, 01 Jan. 2020

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Kimio Yonesaka; Eiji Iwama; Hidetoshi Hayashi; Shinichiro Suzuki; Ryoji Kato; Satomi Watanabe; Takayuki Takahama; Junko Tanizaki; Kaoru Tanaka; Masayuki Takeda; Kazuko Sakai; Koichi Azuma; Yasutaka Chiba; Shinji Atagi; Kazuto Nishio; Isamu Okamoto; Kazuhiko Nakagawa
Scientific reports, 20 Dec. 2019

Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
Yoshikane Nonagase; Masayuki Takeda; Koichi Azuma; Hidetoshi Hayashi; Koji Haratani; Kaoru Tanaka; Kimio Yonesaka; Hidenobu Ishii; Tomoaki Hoshino; Kazuhiko Nakagawa
Thoracic cancer, Oct. 2019

Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Kohei Otsubo; Kazuko Sakai; Masafumi Takeshita; Daijiro Harada; Koichi Azuma; Keiichi Ota; Hiroaki Akamatsu; Koichi Goto; Atsushi Horiike; Takayasu Kurata; Noriaki Nakagaki; Kaname Nosaki; Eiji Iwama; Yoichi Nakanishi; Kazuto Nishio; Isamu Okamoto
The oncologist, Aug. 2019

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tokiyoshi Tanegashima; Yosuke Togashi; Koichi Azuma; Akihiko Kawahara; Ko Ideguchi; Daisuke Sugiyama; Fumio Kinoshita; Jun Akiba; Eiji Kashiwagi; Ario Takeuchi; Takuma Irie; Katsunori Tatsugami; Tomoaki Hoshino; Masatoshi Eto; Hiroyoshi Nishikawa
Clinical cancer research : an official journal of the American Association for Cancer Research, 01 Aug. 2019

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.
Shinkichi Takamori; Kazuki Takada; Koichi Azuma; Tomoko Jogo; Mototsugu Shimokawa; Gouji Toyokawa; Fumihiko Hirai; Tetsuzo Tagawa; Akihiko Kawahara; Jun Akiba; Isamu Okamoto; Yoichi Nakanishi; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
Annals of surgical oncology, Jun. 2019

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Taichi Matsubara; Kazuki Takada; Koichi Azuma; Shinkichi Takamori; Gouji Toyokawa; Akira Haro; Atsushi Osoegawa; Tetsuzo Tagawa; Akihiko Kawahara; Jun Akiba; Isamu Okamoto; Yoichi Nakanishi; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
Annals of surgical oncology, Jun. 2019

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Haruhiro Saito; Tatsuro Fukuhara; Naoki Furuya; Kana Watanabe; Shunichi Sugawara; Shunichiro Iwasawa; Yoshio Tsunezuka; Ou Yamaguchi; Morihito Okada; Kozo Yoshimori; Ichiro Nakachi; Akihiko Gemma; Koichi Azuma; Futoshi Kurimoto; Yukari Tsubata; Yuka Fujita; Hiromi Nagashima; Gyo Asai; Satoshi Watanabe; Masaki Miyazaki; Koichi Hagiwara; Toshihiro Nukiwa; Satoshi Morita; Kunihiko Kobayashi; Makoto Maemondo
The Lancet. Oncology, May 2019

Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
Hiroaki Akamatsu; Yasuhiro Koh; Isamu Okamoto; Daichi Fujimoto; Akihiro Bessho; Koichi Azuma; Satoshi Morita; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Lung cancer (Amsterdam, Netherlands), May 2019

Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy.
Norikazu Matsuo; Koichi Azuma; Tetsuro Sasada
Oncotarget, 08 Mar. 2019

Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.
Norikazu Matsuo; Koichi Azuma; Satoshi Hattori; Junya Ohtake; Akihiko Kawahara; Hidenobu Ishii; Takaaki Tokito; Kazuhiko Yamada; Yuji Shibata; Tadasuke Shimokawaji; Tetsuro Kondo; Terufumi Kato; Haruhiro Saito; Kouzo Yamada; Tetsuro Sasada; Tomoaki Hoshino
International journal of cancer, 01 Mar. 2019

Screening system for epidermal growth factor receptor mutation detection in cytology cell-free DNA of cerebrospinal fluid based on assured sample quality.
Akihiko Kawahara; Hideyuki Abe; Kazuya Murata; Hidenobu Ishii; Koichi Azuma; Yorihiko Takase; Satoshi Hattori; Yoshiki Naito; Jun Akiba
Cytopathology : official journal of the British Society for Clinical Cytology, Mar. 2019

Prognostic Value of Serum Tumor Markers in Patients With Stage III NSCLC Treated With Chemoradiotherapy.
Takaaki Tokito; Koichi Azuma; Kazuhiko Yamada; Yoshiko Naito; Norikazu Matsuo; Hidenobu Ishii; Hiroki Natori; Takashi Kinoshita; Tomoaki Hoshino
In vivo (Athens, Greece), 2019

Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Kazuki Takada; Mototsugu Shimokawa; Kensuke Tanaka; Kenichi Kohashi; Akira Haro; Atsushi Osoegawa; Tetsuzo Tagawa; Koichi Azuma; Isamu Okamoto; Yoshinao Oda; Masaki Mori
PloS one, 2019

Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Yoshiaki Zaizen; Takaaki Tokito; Ken Masuda; Koichi Azuma; Yoshiki Naito; Shingo Tsuneyoshi; Yuki Sakazaki; Norikazu Matsuo; Hidenobu Ishii; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Internal medicine (Tokyo, Japan), 01 Dec. 2018

Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
Eiji Iwama; Kazuko Sakai; Koichi Azuma; Daijiro Harada; Kaname Nosaki; Katsuyuki Hotta; Makoto Nishio; Takayasu Kurata; Tatsuro Fukuhara; Hiroaki Akamatsu; Koichi Goto; Takayuki Shimose; Junji Kishimoto; Yoichi Nakanishi; Kazuto Nishio; Isamu Okamoto
Cancer science, Dec. 2018

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
Shinkichi Takamori; Kazuki Takada; Gouji Toyokawa; Koichi Azuma; Mototsugu Shimokawa; Tomoko Jogo; Yuichi Yamada; Fumihiko Hirai; Tetsuzo Tagawa; Akihiko Kawahara; Jun Akiba; Isamu Okamoto; Yoichi Nakanishi; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
Anticancer research, Oct. 2018

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
Shinkichi Takamori; Kazuki Takada; Koichi Azuma; Yumiko Jogo; Fumihiko Kinoshita; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Takaki Akamine; Gouji Toyokawa; Fumihiko Hirai; Tetsuzo Tagawa; Isamu Okamoto; Yoichi Nakanishi; Akihiko Kawahara; Jun Akiba; Yoshinao Oda; Yoshihiko Maehara
Anticancer research, Oct. 2018

Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
Hideyuki Abe; Akihiko Kawahara; Koichi Azuma; Yuichi Murakami; Yorihiko Takase; Yoshiki Naito; Jun Akiba
Diagnostic cytopathology, Sep. 2018

Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.
Takeharu Ono; Koichi Azuma; Akihiko Kawahara; Tetsuro Sasada; Norikazu Matsuo; Tatsuyuki Kakuma; Hiroyuki Kamimura; Ririko Maeda; Chikayuki Hattori; Kotaro On; Kei Nagata; Fumihiko Sato; Shun-Ich Chitose; Buichiro Shin; Takeichiro Aso; Jun Akiba; Hirohito Umeno
Head & neck, Sep. 2018

Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Haruyasu Murakami; Hiroshi Nokihara; Hidetoshi Hayashi; Takashi Seto; Keunchil Park; Koichi Azuma; Chun-Ming Tsai; James Chih-Hsin Yang; Makoto Nishio; Sang-We Kim; Katsuyuki Kiura; Akira Inoue; Koji Takeda; Jin-Hyoung Kang; Tomoki Nakagawa; Kentaro Takeda; Rio Akazawa; Yuichiro Kaneko; Masashi Shimazaki; Satoshi Morita; Masahiro Fukuoka; Kazuhiko Nakagawa
Cancer science, Sep. 2018

The assessment of correlation and prognosis among 18F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients.
Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Shinzo Takamori; Jun Akiba; Kiminori Fujimoto; Axel Rominger; Takamichi Murakami; Kazunari Ishii; Masatoshi Ishibashi
Oncotarget, 10 Aug. 2018

Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.
Midori Tanaka; Hidenobu Ishii; Hayato Moribuchi; Yoshiko Naito; Norikazu Matsuo; Masayuki Nakamura; Takaaki Tokito; Koichi Azuma; Kazuhiko Yamada; Tomoaki Hoshino
Investigational new drugs, Aug. 2018

ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Koichi Azuma; Makoto Nishio; Hidetoshi Hayashi; Katsuyuki Kiura; Miyako Satouchi; Shunichi Sugawara; Toyoaki Hida; Yasuo Iwamoto; Akira Inoue; Koji Takeda; Satoshi Ikeda; Tomoki Nakagawa; Kentaro Takeda; Seitaro Asahina; Kanji Komatsu; Satoshi Morita; Masahiro Fukuoka; Kazuhiko Nakagawa
Cancer science, Aug. 2018

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Daisuke Shibahara; Kentaro Tanaka; Eiji Iwama; Naoki Kubo; Keiichi Ota; Koichi Azuma; Taishi Harada; Jiro Fujita; Yoichi Nakanishi; Isamu Okamoto
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Jul. 2018

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIs.
Ken Masuda; Takaaki Tokito; Koichi Azuma; Eriko Yanagida; Masayuki Nakamura; Yoshiko Naito; Norikazu Matsuo; Hidenobu Ishii; Kazuhiko Yamada; Jun Akiba; Tomoaki Hoshino
Thoracic cancer, Jun. 2018

Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
Hiroaki Takeoka; Kazuhiko Yamada; Yoshiko Naito; Norikazu Matsuo; Hidenobu Ishii; Takaaki Tokito; Koichi Azuma; Masao Ichiki; Tomoaki Hoshino
Anticancer research, Jun. 2018

Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.
Yoshiko Naito; Kazuhiko Yamada; Yohei Imamura; Hidenobu Ishii; Norikazu Matsuo; Takaaki Tokito; Takashi Kinoshita; Koichi Azuma; Tomoaki Hoshino
Medical oncology (Northwood, London, England), 02 Apr. 2018

Correlations between dual-phase 18F-FDG uptake and clinicopathologic and biological markers in predicting the aggressiveness of breast cancer
Hayato Kaida; Koichi Azuma; Uhi Toh; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Jun Akiba; Nobuhiro Tahara; Axel Rominger; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
Hellenic Journal of Nuclear Medicine, 01 Jan. 2018, [Reviewed]

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Kazuki Takada; Gouji Toyokawa; Koichi Azuma; Shinkichi Takamori; Tomoko Jogo; Fumihiko Hirai; Tetsuzo Tagawa; Akihiko Kawahara; Jun Akiba; Isamu Okamoto; Yoichi Nakanishi; Yoshinao Oda; Tomoaki Hoshino; Yoshihiko Maehara
In vivo (Athens, Greece), 2018

Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.
Takeharu Ono; Koichi Azuma; Akihiko Kawahara; Tetsuro Sasada; Satoshi Hattori; Fumihiko Sato; Buichiro Shin; Shun-Ich Chitose; Jun Akiba; Umeno Hirohito
Oncotarget, 03 Nov. 2017

Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed.
Goushi Matama; Takaaki Tokito; Hiroaki Takeoka; Yuki Hiraoka; Norikazu Matsuo; Masayuki Nakamura; Hidenobu Ishii; Takashi Kinoshita; Koichi Azuma; Kazuhiko Yamada; Tomoaki Hoshino
Investigational new drugs, Oct. 2017

Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.
Hidenobu Ishii; Koichi Azuma; Akihiko Kawahara; Norikazu Matsuo; Takaaki Tokito; Takashi Kinoshita; Kazuhiko Yamada; Tetsuro Sasada; Jun Akiba; Tomoaki Hoshino
Oncotarget, 22 Sep. 2017

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.
Yuichi Murakami; Kahori Sonoda; Hideyuki Abe; Kosuke Watari; Daiki Kusakabe; Koichi Azuma; Akihiko Kawahara; Jun Akiba; Chitose Oneyama; Jonathan A Pachter; Kazuko Sakai; Kazuto Nishio; Michihiko Kuwano; Mayumi Ono
Oncotarget, 19 Sep. 2017

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.
Kentaro Tanaka; Kaname Nosaki; Kohei Otsubo; Koichi Azuma; Shinya Sakata; Hiroshi Ouchi; Ryotaro Morinaga; Hiroshi Wataya; Akiko Fujii; Noriaki Nakagaki; Nobuko Tsuruta; Masafumi Takeshita; Eiji Iwama; Taishi Harada; Yoichi Nakanishi; Isamu Okamoto
Oncotarget, 15 Sep. 2017

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Takehito Shukuya; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura
Lancet (London, England), 01 Jul. 2017

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
Norikazu Matsuo; Koichi Azuma; Kazuko Sakai; Satoshi Hattori; Akihiko Kawahara; Hidenobu Ishii; Takaaki Tokito; Takashi Kinoshita; Kazuhiko Yamada; Kazuto Nishio; Tomoaki Hoshino
Scientific Reports, 04 Nov. 2016, [Reviewed]

The correlation between FDG uptake and biological molecular markers in pancreatic cancer patients
Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Masafumi Yasunaga; Yuhei Kitasato; Satoshi Hattori; Tomoki Taira; Hiroki Ureshino; Masayoshi Kage; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
EUROPEAN JOURNAL OF RADIOLOGY, Oct. 2016, [Reviewed]

Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takayuki Takahama; Kazuko Sakai; Masayuki Takeda; Koichi Azuma; Toyoaki Hida; Masataka Hirabayashi; Tetsuya Oguri; Hiroshi Tanaka; Noriyuki Ebi; Toshiyuki Sawa; Akihiro Bessho; Motoko Tachihara; Hiroaki Akamatsu; Shuji Bandoh; Daisuke Himeji; Tatsuo Ohira; Mototsugu Shimokawa; Yoichi Nakanishi; Kazuhiko Nakagawa; Kazuto Nishio
Oncotarget, 06 Sep. 2016

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
Koichi Azuma; Tomonori Hirashima; Nobuyuki Yamamoto; Isamu Okamoto; Toshiaki Takahashi; Makoto Nishio; Taizo Hirata; Kaoru Kubota; Kazuo Kasahara; Toyoaki Hida; Hiroshige Yoshioka; Kaoru Nakanishi; Shiro Akinaga; Kazuto Nishio; Tetsuya Mitsudomi; Kazuhiko Nakagawa
ESMO Open, Jul. 2016, [Reviewed]

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial
Masayuki Takeda; Takeharu Yamanaka; Takashi Seto; Hidetoshi Hayashi; Koichi Azuma; Morihito Okada; Shunichi Sugawara; Haruko Daga; Tomonori Hirashima; Kimio Yonesaka; Yoshiko Urata; Haruyasu Murakami; Haruhiro Saito; Akihito Kubo; Toshiyuki Sawa; Eiji Miyahara; Naoyuki Nogami; Kazuhiko Nakagawa; Yoichi Nakanishi; Isamu Okamoto
CANCER, Apr. 2016, [Reviewed]

Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples
Hidenobu Ishii; Koichi Azuma; Kazuko Sakai; Akihiko Kawahara; Kazuhiko Yamada; Takaaki Tokito; Isamu Okamoto; Kazuto Nishio; Tomoaki Hoshino
ONCOTARGET, Oct. 2015, [Reviewed]

A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911
Kazuhiko Yamada; Hiromi Aono; Yukio Hosomi; Hiroaki Okamoto; Terufumi Kato; Yuko Komase; Masanori Nishikawa; Koichi Azuma; Hiroaki Takeoka; Yusuke Okuma; Yoshiro Nakahara; Akira Sato; Mari S. Oba; Satoshi Morita; Hideo Kunitoh; Koshiro Watanabe
EUROPEAN JOURNAL OF CANCER, Sep. 2015, [Reviewed]

Induction of PD-L1 expression by the EML4-ALK oncoprotein and down stream signaling pathways in non-small cell lung cancer
Keiichi Ota; Koichi Azuma; Akihiko Kawahara; Satoshi Hattori; Eiji Iwama; Junko Tanizaki; Taishi Harada; Koichiro Matsumoto; Koichi Takayama; Shinzo Takamori; Masayoshi Kage; Tomoaki Hoshino; Yoichi Nakanishi; Isamu Okamoto
Clinical Cancer Research, 01 Sep. 2015

Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis.
Morihiro Tajiri; Masaki Okamoto; Kiminori Fujimoto; Takeshi Johkoh; Junya Ono; Masaki Tominaga; Koichi Azuma; Tomotaka Kawayama; Shoichiro Ohta; Kenji Izuhara; Tomoaki Hoshino
Respiratory investigation, Mar. 2015, [Reviewed]

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
Isamu Okamoto; Masaki Miyazaki; Masayuki Takeda; Masaaki Terashima; Koichi Azuma; Hidetoshi Hayashi; Hiroyasu Kaneda; Takayasu Kurata; Junji Tsurutani; Takashi Seto; Fumihiko Hirai; Koichi Konishi; Akiko Sarashina; Nobutaka Yagi; Rolf Kaiser; Kazuhiko Nakagawa
JOURNAL OF THORACIC ONCOLOGY, Feb. 2015, [Reviewed]

Phase I study of carboplatin combined with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer.
Hiroaki Takeoka; Kazuhiko Yamada; Koichi Azuma; Yoshiaki Zaizen; Fumie Yamashita; Tsukasa Yoshida; Yoshiko Naito; Yusuke Okayama; Maki Miyamoto; Tomoaki Hoshino
Japanese journal of clinical oncology, May 2014, [Reviewed]

The difference in relationship between F-18-FDG uptake and clinicopathological factors on thyroid, esophageal, and lung cancers
Hayato Kaida; Akihiko Kawahara; Masanobu Hayakawa; Satoshi Hattori; Seiji Kurata; Kiminori Fujimoto; Koichi Azuma; Yasumitsu Hirose; Shinzo Takamori; Yuji Hiromatsu; Tadashi Nakashima; Hiromasa Fujita; Masayoshi Kage; Naofumi Hayabuchi; Masatoshi Ishibashi
NUCLEAR MEDICINE COMMUNICATIONS, Jan. 2014, [Reviewed]

Humoral Immune Responses to EGFR-Derived Peptides Predict Progression-Free and Overall Survival of Non-Small Cell Lung Cancer Patients Receiving Gefitinib
Koichi Azuma; Nobukazu Komatsu; Satoshi Hattori; Satoko Matsueda; Akihiko Kawahara; Tetsuro Sasada; Kyogo Itoh; Tomoaki Hoshino
PLOS ONE, Jan. 2014, [Reviewed]

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Teppei Yamada; Koichi Azuma; Emi Muta; Jintaek Kim; Shunichi Sugawara; Guang Lan Zhang; Satoko Matsueda; Yuri Kasama-Kawaguchi; Yuichi Yamashita; Takuto Yamashita; Kazuto Nishio; Kyogo Itoh; Tomoaki Hoshino; Tetsuro Sasada
PLOS ONE, Nov. 2013, [Reviewed]

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
Fumie Yamashita; Koichi Azuma; Tsukasa Yoshida; Kazuhiko Yamada; Akihiko Kawahara; Satoshi Hattori; Hiroaki Takeoka; Yoshiaki Zaizen; Tomotaka Kawayama; Masayoshi Kage; Tomoaki Hoshino
PLOS ONE, Aug. 2013, [Reviewed]

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Tsukasa Yoshida; Kazuhiko Yamada; Koichi Azuma; Akihiko Kawahara; Hideyuki Abe; Satoshi Hattori; Fumie Yamashita; Yoshiaki Zaizen; Masayoshi Kage; Tomoaki Hoshino
Medical oncology (Northwood, London, England), Mar. 2013, [Reviewed]

Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Yoshiaki Zaizen; Koichi Azuma; Seiji Kurata; Eiji Sadashima; Satoshi Hattori; Tetsuro Sasada; Yohei Imamura; Hayato Kaida; Akihiko Kawahara; Takashi Kinoshita; Masatoshi Ishibashi; Tomoaki Hoshino
European journal of radiology, Dec. 2012, [Reviewed]

A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer
Akihiko Kawahara; Tomoki Taira; Koichi Azuma; Masaki Tominaga; Satoshi Hattori; Mayuko Kawahara; Hideyuki Abe; Tomohiko Yamaguchi; Jun Akiba; Shinzo Takamori; Akihiro Hayashi; Masayoshi Kage
LUNG CANCER, Oct. 2012, [Reviewed]

Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia.
Takashi Kinoshita; Koichi Azuma; Tetsuro Sasada; Masaki Okamoto; Satoshi Hattori; Youhei Imamura; Kazuhiko Yamada; Morihiro Tajiri; Tsukasa Yoshida; Yoshiaki Zaizen; Akihiko Kawahara; Kiminori Fujimoto; Tomoaki Hoshino
Oncology letters, Sep. 2012, [Reviewed]

NDRG1/Cap43/Drg-1 may Predict Tumor Angiogenesis and Poor Outcome in Patients with Lung Cancer
Koichi Azuma; Akihiko Kawahara; Satoshi Hattori; Tomoki Taira; Junji Tsurutani; Kosuke Watari; Tomohiro Shibata; Yuichi Murakami; Shinzo Takamori; Mayumi Ono; Hiroto Izumi; Masayoshi Kage; Takashi Yanagawa; Kazuhiko Nakagawa; Tomoaki Hoshino; Michihiko Kuwano
JOURNAL OF THORACIC ONCOLOGY, May 2012, [Reviewed]

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment
Koichi Azuma; Isamu Okamoto; Akihiko Kawahara; Tomoki Taira; Kazutaka Nakashima; Satoshi Hattori; Takashi Kinoshita; Masayuki Takeda; Kazuhiko Nakagawa; Shinzo Takamori; Michihiko Kuwano; Mayumi Ono; Masayoshi Kage
JOURNAL OF THORACIC ONCOLOGY, Jan. 2012, [Reviewed]

Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy
Yohei Imamura; Koichi Azuma; Seiji Kurata; Satoshi Hattori; Tetsuro Sasada; Takashi Kinoshita; Masaki Okamoto; Tomotaka Kawayama; Hayato Kaida; Masatoshi Ishibashi; Hisamichi Aizawa
LUNG CANCER, Jan. 2011, [Reviewed]

The close correlation between 8-hydroxy-2 '-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer
Akihiko Kawahara; Koichi Azuma; Satoshi Hattori; Kazutaka Nakashima; Yuji Basaki; Jun Akiba; Sinzo Takamori; Hisamichi Aizawa; Takashi Yanagawa; Hiroto Izumi; Kimitoshi Kohno; Suminori Kono; Masayoshi Kage; Michihiko Kuwano; Mayumi Ono
HUMAN PATHOLOGY, Jul. 2010, [Reviewed]

Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
Akihiko Kawahara; Chizuko Yamamoto; Kazutaka Nakashima; Koichi Azuma; Satoshi Hattori; Masaki Kashihara; Hisamichi Aizawa; Yuji Basaki; Michihiko Kuwano; Masayoshi Kage; Tetsuya Mitsudomi; Mayumi Ono
CLINICAL CANCER RESEARCH, Jun. 2010, [Reviewed]

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation
Koichi Azuma; Tetsuro Sasada; Akihiko Kawahara; Satoshi Hattori; Takashi Kinoshita; Sinzo Takamori; Masao Ichiki; Youhei Imamura; Jiro Ikeda; Masayoshi Kage; Michihiko Kuwano; Hisamichi Aizawa
CANCER CHEMOTHERAPY AND PHARMACOLOGY, Jul. 2009, [Reviewed]

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel
Koichi Azuma; Tetsuro Sasada; Akihiko Kawahara; Sinzo Takamori; Satoshi Hattori; Jiro Ikeda; Kyogo Itoh; Akira Yamada; Masayoshi Kage; Michihiko Kuwano; Hisamichi Aizawa
LUNG CANCER, Jun. 2009, [Reviewed]

Correlation of decreased survival and IL-18 in bone metastasis
Masaki Okamoto; Koichi Azuma; Tomoaki Hoshino; Haruki Imaoka; Jiro Ikeda; Takashi Kinoshita; Shinzo Takamori; Koichi Ohshima; Nobutaka Edakuni; Seiya Kato; Tomoaki Iwanaga; Hisamichi Aizawa
Internal Medicine, 2009, [Reviewed]

Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy
Koichi Azuma; Yoshihiro Komohara; Tetsuro Sasada; Yasuhiro Terazaki; Jiro Ikeda; Tomoaki Hoshino; Kyogo Itoh; Akira Yamada; Hisamichi Aizawa
CANCER SCIENCE, Sep. 2007, [Reviewed]

Relevance between PD-L1 expression combined with tumor infiltrating lymphocytes and prognosis in advanced hypopharyngeal squamous cell carcinoma.
Takeharu Ono; Koichi Azuma; Akihiko Kawahara; Tetsuro Sasada; Satoshi Hattori; Fumihiko Sato; Shun-Ich Chitose; Buichiro Shin; Jun Akiba; Hirohito Umeno
JOURNAL OF CLINICAL ONCOLOGY, May 2017

Prognostic impact of F-18-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients.
Hayato Kaida; Koichi Azuma; Akihiko Kawahara; Eiji Sadashima; Satoshi Hattori; Jun Akiba; Axel Rominger; Shinzo Takamori; Kiminori Fujimoto; Makoto Hosono; Kazunari Ishii; Takamichi Murakami; Masatoshi Ishibashi
JOURNAL OF NUCLEAR MEDICINE, May 2017

Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naive ALK fusion positive non-small cell lung cancer (ALK plus NSCLC).
Yuichi Takiguchi; Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Hiroshi Kuriki; Naohito Inagaki; Tomohiro Tanaka; Tomohide Tamura
JOURNAL OF CLINICAL ONCOLOGY, May 2017

Association of EGFR Exon 19 Deletion and EGFR-TKI treatment duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
Norikazu Matsuo; Koichi Azuma; Kazuko Sakai; Akihiko Kawahara; Hidenobu Ishii; Takaaki Tokito; Takashi Kinoshita; Kazuhiko Yamada; Kazuto Nishio; Tomoaki Hoshino
JOURNAL OF THORACIC ONCOLOGY, Jan. 2017

Phase I/II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations
Toshio Shimizu; Hiroshi Nokihara; Haruyasu Murakami; Takashi Seto; Makoto Nishio; Koji Takeda; Akira Inoue; Katsuyuki Kiura; Koichi Azuma; Anne Keating; Andrew Krivoshik; Koichi Uegaki; Kentaro Takeda; Kanji Komatsu; Satoshi Morita; Masahiro Fukuoka; Kazuhiko Nakagawa
ANNALS OF ONCOLOGY, Nov. 2015

Bevacizumab beyond disease progression in advanced non-squamous NSCLC (WJOG 5910L): a randomized phase II trial
Takashi Seto; Masayuki Takeda; Hidetoshi Hayashi; Koichi Azuma; Morihito Okada; Shunichi Sugawara; Takeharu Yamanaka; Kazuhiko Nakagawa; Yoichi Nakanishi; Isamu Okamoto
ANNALS OF ONCOLOGY, Nov. 2015

A prospective biomarker study in afatinib-treated patients with EGFR-mutation positive non-small cell lung
Eiji Iwama; Kazuko Sakai; Koichi Azuma; Kaname Nozaki; Daijiro Harada; Katsuyuki Hotta; Fumiyoshi Ohyanagi; Yoichi Nakanishi; Kazuto Nishio; Isamu Okamoto
ANNALS OF ONCOLOGY, Nov. 2015

Noninvasive detection of acquired T790M mutation in NSCLC patients treated with EGFR-TKI using digital PCR of plasma
Hidenobu Ishii; Koichi Azuma; Kazuko Sakai; Takaaki Tokito; Kazuhiko Yamada; Kazuto Nishio; Tomoaki Hoshibo
ANNALS OF ONCOLOGY, Nov. 2015

Digital PCR Analysis of Plasma Cell-Free DNA as a Noninvasive Detection of the Drug Resistance Mechanisms in EGFR Mutant NSCLC
Hidenobu Ishii; Koichi Azuma; Kazuko Sakai; Takaaki Tokito; Kazuhiko Yamada; Kazuto Nishio; Tomoaki Hoshino
JOURNAL OF THORACIC ONCOLOGY, Sep. 2015

A Multicenter Prospective Biomarker Study in Afatinib-Treated Patients with EGFR-Mutation Positive Non-Small Cell Lung Cancer
Koichi Azuma; Eiji Iwama; Kazuko Sakai; Kaname Nozaki; Daijiro Harada; Katsuyuki Hotta; Fumiyoshi Ohyanagi; Takayasu Kurata; Hiroaki Akamatsu; Koichi Goto; Tatsuro Fukuhara; Yoichi Nakanishi; Isamu Okamoto; Kazuto Nishio
JOURNAL OF THORACIC ONCOLOGY, Sep. 2015

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non-small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.
Masayuki Takeda; Takashi Seto; Hidetoshi Hayashi; Morihito Okada; Koichi Azuma; Shunichi Sugawara; Haruko Daga; Tomonori Hirashima; Kimio Yonesaka; Yoshiko Urata; Haruyasu Murakami; Haruhiro Saito; Akihito Kubo; Toshiyuki Sawa; Eiji Miyahara; Naoyuki Nogami; Takeharu Yamanaka; Yoichi Nakanishi; Kazuhiko Nakagawa; Isamu Okamoto
JOURNAL OF CLINICAL ONCOLOGY, May 2015

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor
Koichi Azuma; Akihiko Kawahara; Kahori Sonoda; Kazutaka Nakashima; Kousuke Tashiro; Kosuke Watari; Hiroto Izumi; Masayoshi Kage; Michihiko Kuwano; Mayumi Ono; Tomoaki Hoshino
Oncotarget, 2014

PHASE I DOSE ESCALATION STUDY OF PEMETREXED AND CARBOPLATIN IN CHEMOTHEARPY-NAIVE ELDERLY PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER.
Hiroaki Takeoka; Kazuhiko Yamada; Yoshiaki Zaizen; Fumie Shimamatsu; Koichi Azuma; Tomoaki Hoshino
JOURNAL OF THORACIC ONCOLOGY, Nov. 2013

Phase I dose escalation study of pemetrexed and carboplatin in chemotherapy-naive elderly patients with advanced nonsquamous non-small cell lung cancer.
Kazuhiko Yamada; Hiroaki Takeoka; Yoshiaki Zaizen; Fumie Shimamatsu; Koichi Azuma; Tomoaki Hoshino
JOURNAL OF CLINICAL ONCOLOGY, May 2013

ZOLEDRONIC ACID-INDUCED REGRESSION OF MULTIPLE METASTASES AT NONSKELETAL SITES
Junji Tsurutani; Kunio Okamoto; Chihior Makimura; Koichi Azuma; Masayuki Takeda; Ken Takezawa; Wataru Okamoto; Hidemi Kiyota; Hidetoshi Hayashi; Kaoru Tanaka; Junko Tanizaki; Isamu Okamoto; Nagahiro Saijoh; Masahiro Fukuoka; Kazuhiko Nakagawa
ANNALS OF ONCOLOGY, Nov. 2010, [Reviewed]

特許第7304558号, JP2018045465, がん免疫療法の予後予測のためのバイオマーカー
笹田 哲朗; 松尾 規和; 東 公一; 星野 友昭

WO2019-117132, JP2018045465, がん免疫療法の予後予測のためのバイオマーカー
笹田 哲朗; 松尾 規和; 東 公一; 星野 友昭

特許第6463675号, 特願2015-522950, 上皮成長因子受容体チロシンキナーゼ阻害薬の治療効果を予測する方法
東 公一; 星野 友昭; 服部 聡; 伊東 恭悟; 笹田 哲朗; 小松 誠和; 松枝 智子

WO2014-203918, JP2014066100, 上皮成長因子受容体チロシンキナーゼ阻害薬の治療効果を予測する方法
東 公一; 星野 友昭; 服部 聡; 伊東 恭悟; 笹田 哲朗; 小松 誠和; 松枝 智子

胸部悪性腫瘍の治療及び研究を頑張っています